All updated as on -
The world market for human milk oligosaccharides (HMO) was worth $125.29 million in 2022. It's expected to grow to $332.16 million by 2030, with a compound annual growth rate (CAGR) of 16.1% from 2023 to 2030.
Human milk oligosaccharide (HMO) is a type of structurally complicated, unconjugated glycans that is found in large amounts in human milk. HMOs are only partially broken down in the digestive system. They get to the gut whole and shape the microbiota there. Key players in the Human Milk Oligosaccharides (HMO) market are working on a number of new methods to make them because they are good for the immune system. These include separating HMO from cow milk, using expensive methods like chemical or enzymatic synthesis, or using bacteria to make them. Human Milk Oligosaccharides (HMO) goods on the market are pricey because a lot of human milk has to be synthesized to make a little HMO. As a result, methods for synthesis and extraction are getting better thanks to ongoing research and development.
Animals that ate human milk oligosaccharides and other ingredients in baby formula moved on to a new stage of infant nutrition. Protecting babies' digestive systems and keeping them safe from pathogens are the best things that human milk oligosaccharides do. The world market for human milk oligosaccharides is expected to grow because of these things. Human milk oligosaccharides have been shown to improve an infant's gut health when added to their regular food. It also makes it easier to get rid of bacteria and particles in the intestine, which makes colonization better. An option for moms who can't breastfeed because they're missing teeth is an HMO. To make sure that there is a market for baby formula ingredients, chemical synthesis and fermentation are used to make HMOs. According to the WHO, the world's population will hit 9.5 billion by 2050, and about a billion people will be born each year for the next ten years.
According to the UN, more than 250 babies are born every minute around the world. Every day, 353,000 babies are born, which means that more than 130 million babies are born every year. This is the direct cause of the rise in the use of baby formula around the world. There are a number of other reasons for this rise in usage as well. Some of these are more women going back to work after giving birth, mothers not being able to breastfeed, and better food choices for babies who are still growing. The UN says that by 2050, there will be 9.6 billion people living in the world. Human milk oligosaccharides are a main ingredient in many types of infant formula and baby food made in the infant nutrition business. Human milk oligosaccharides will likely sell better as an ingredient in baby formula in the coming years because the population is always growing. The National Bureau of Statistics of China says that 15.23 million babies were born in the country in 2018. This is great news for makers because it means more babies will be born. China is likely to bring in a lot of money for the Human Milk Oligosaccharides market because of this.
The process of making and selling HMO goods is hard, expensive, and uncertain. The success of product creation depends on the state of technology, the needs of consumers, and the laws and rules that apply. For the research and development of a certain type of HMO to be used to make dietary supplements or other useful foods like prebiotics, a lot of money has to be spent. These goods are made in a way that follows international rules for food safety. To make and extract different other useful ingredients, you also need highly sterile and technical tools and methods. Because making the product costs a lot, the price of the finished item is also very high. The cost of marketing and distributing the goods goes up even more. People are aware that these pricey functional foods are good for them, but they can't afford to buy them because of the high prices. The effect of the factor is stronger in growing countries where people are price conscious, like in some Asian and African countries.
The Human Milk Oligosaccharides (HMO) market is expected to make a lot of money over the next few years. This is because HMO is being used in more functional foods and drinks and infant formula, the product line is getting better and better with technology all the time, people are becoming more health conscious, and the dairy industry is growing quickly. Many different types and amounts of HMOs are available because they are important parts of human milk. They are new ingredients that need to be approved by the government. Generally Recognized as Safe (GRAS) rules apply to nutrition supplements in the U.S., but HMOs are meant to be used in food. This means that DuPont's CARE4U can be used in baby formula and toddler foods in the United States. Due to a higher demand for HMOs, two of them have been through a new food safety review in Europe. Both passed and were approved by the European Commission.
HMOs have been used for a long time in baby formula and human milk. But the parts are different, and HMOs aren't found in other foods. How to get into the Human Milk Oligosaccharides (HMO) market for new and different HMOs as a nutrition supplement? First, get GRAS approval for use in food, and then use it as a supplement in the same way. These kinds of alerts have been sent to 2'-O-fucosyllactose, 2'-fucosyllactose, and lacto-N-neotetraose.
Report Coverage
Global Human Milk Oligosaccharides (HMO) research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Human Milk Oligosaccharides (HMO) report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Human Milk Oligosaccharides (HMO) competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Human Milk Oligosaccharides (HMO) market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Human Milk Oligosaccharides (HMO) market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Human Milk Oligosaccharides (HMO) market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Nestle Health Science, Medolac Laboratories, Inbiose NV, Biosynth Carbosynth, Elicityl S.A., Chr. Hansen Holding A/S, Glycosyn, DuPont Nutrition & Biosciences, Dextra Laboratories Ltd, ROYAL DSM, DSM (Netherlands), BASF SE (Germany), Gnubiotics Sciences S.A ( Switzerland), Abbott Laboratories (US), Royal Friesland Campina N.V (Netherlands), Dextra Laboratories (UK).
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Human Milk Oligosaccharides (HMO) market based on the below-mentioned segments:
Global Human Milk Oligosaccharides (HMO) Market, By Type
2’FL
3’FL
3’SL
6’SL
Global Human Milk Oligosaccharides (HMO) market, By Application
Infant Formula
Functional Food & Beverage
Food Supplements
Global Human Milk Oligosaccharides (HMO) Market, By Distribution Channel
Hypermarkets & Supermarkets
Drug Store or Pharmacy
Mass Merchandiser
Departmental Stores
Mono-brand Stores
Specialty Stores
Online Sales Channel
Global Human Milk Oligosaccharides (HMO) market, Regional Analysis
Human milk oligosaccharide (HMO) is a type of structurally complicated, unconjugated glycans that is found in large amounts in human milk. HMOs are only partially broken down in the digestive system. They get to the gut whole and shape the microbiota there. Key players in the Human Milk Oligosaccharides (HMO) market are working on a number of new methods to make them because they are good for the immune system. These include separating HMO from cow milk, using expensive methods like chemical or enzymatic synthesis, or using bacteria to make them. Human Milk Oligosaccharides (HMO) goods on the market are pricey because a lot of human milk has to be synthesized to make a little HMO. As a result, methods for synthesis and extraction are getting better thanks to ongoing research and development.
Animals that ate human milk oligosaccharides and other ingredients in baby formula moved on to a new stage of infant nutrition. Protecting babies' digestive systems and keeping them safe from pathogens are the best things that human milk oligosaccharides do. The world market for human milk oligosaccharides is expected to grow because of these things. Human milk oligosaccharides have been shown to improve an infant's gut health when added to their regular food. It also makes it easier to get rid of bacteria and particles in the intestine, which makes colonization better. An option for moms who can't breastfeed because they're missing teeth is an HMO. To make sure that there is a market for baby formula ingredients, chemical synthesis and fermentation are used to make HMOs. According to the WHO, the world's population will hit 9.5 billion by 2050, and about a billion people will be born each year for the next ten years.
According to the UN, more than 250 babies are born every minute around the world. Every day, 353,000 babies are born, which means that more than 130 million babies are born every year. This is the direct cause of the rise in the use of baby formula around the world. There are a number of other reasons for this rise in usage as well. Some of these are more women going back to work after giving birth, mothers not being able to breastfeed, and better food choices for babies who are still growing. The UN says that by 2050, there will be 9.6 billion people living in the world. Human milk oligosaccharides are a main ingredient in many types of infant formula and baby food made in the infant nutrition business. Human milk oligosaccharides will likely sell better as an ingredient in baby formula in the coming years because the population is always growing. The National Bureau of Statistics of China says that 15.23 million babies were born in the country in 2018. This is great news for makers because it means more babies will be born. China is likely to bring in a lot of money for the Human Milk Oligosaccharides market because of this.
The process of making and selling HMO goods is hard, expensive, and uncertain. The success of product creation depends on the state of technology, the needs of consumers, and the laws and rules that apply. For the research and development of a certain type of HMO to be used to make dietary supplements or other useful foods like prebiotics, a lot of money has to be spent. These goods are made in a way that follows international rules for food safety. To make and extract different other useful ingredients, you also need highly sterile and technical tools and methods. Because making the product costs a lot, the price of the finished item is also very high. The cost of marketing and distributing the goods goes up even more. People are aware that these pricey functional foods are good for them, but they can't afford to buy them because of the high prices. The effect of the factor is stronger in growing countries where people are price conscious, like in some Asian and African countries.
The Human Milk Oligosaccharides (HMO) market is expected to make a lot of money over the next few years. This is because HMO is being used in more functional foods and drinks and infant formula, the product line is getting better and better with technology all the time, people are becoming more health conscious, and the dairy industry is growing quickly. Many different types and amounts of HMOs are available because they are important parts of human milk. They are new ingredients that need to be approved by the government. Generally Recognized as Safe (GRAS) rules apply to nutrition supplements in the U.S., but HMOs are meant to be used in food. This means that DuPont's CARE4U can be used in baby formula and toddler foods in the United States. Due to a higher demand for HMOs, two of them have been through a new food safety review in Europe. Both passed and were approved by the European Commission.
HMOs have been used for a long time in baby formula and human milk. But the parts are different, and HMOs aren't found in other foods. How to get into the Human Milk Oligosaccharides (HMO) market for new and different HMOs as a nutrition supplement? First, get GRAS approval for use in food, and then use it as a supplement in the same way. These kinds of alerts have been sent to 2'-O-fucosyllactose, 2'-fucosyllactose, and lacto-N-neotetraose.
Report Coverage
Global Human Milk Oligosaccharides (HMO) research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Human Milk Oligosaccharides (HMO) report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Human Milk Oligosaccharides (HMO) competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Human Milk Oligosaccharides (HMO) market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Nestle Health Science, Medolac Laboratories, Inbiose NV, Biosynth Carbosynth, Elicityl S.A., Chr. Hansen Holding A/S, Glycosyn, DuPont Nutrition & Biosciences, Dextra Laboratories Ltd, ROYAL DSM, DSM (Netherlands), BASF SE (Germany), Gnubiotics Sciences S.A ( Switzerland), Abbott Laboratories (US), Royal Friesland Campina N.V (Netherlands), Dextra Laboratories (UK). |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Human Milk Oligosaccharides (HMO) Market from 2021 to 2030.
- Market Forecast for Human Milk Oligosaccharides (HMO) Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Human Milk Oligosaccharides (HMO) competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Human Milk Oligosaccharides (HMO)
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Human Milk Oligosaccharides (HMO) market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Human Milk Oligosaccharides (HMO) market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Nestle Health Science, Medolac Laboratories, Inbiose NV, Biosynth Carbosynth, Elicityl S.A., Chr. Hansen Holding A/S, Glycosyn, DuPont Nutrition & Biosciences, Dextra Laboratories Ltd, ROYAL DSM, DSM (Netherlands), BASF SE (Germany), Gnubiotics Sciences S.A ( Switzerland), Abbott Laboratories (US), Royal Friesland Campina N.V (Netherlands), Dextra Laboratories (UK).
Primary Target Market
- Market Players of Human Milk Oligosaccharides (HMO)
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Human Milk Oligosaccharides (HMO) market based on the below-mentioned segments:
Global Human Milk Oligosaccharides (HMO) Market, By Type
2’FL
3’FL
3’SL
6’SL
Global Human Milk Oligosaccharides (HMO) market, By Application
Infant Formula
Functional Food & Beverage
Food Supplements
Global Human Milk Oligosaccharides (HMO) Market, By Distribution Channel
Hypermarkets & Supermarkets
Drug Store or Pharmacy
Mass Merchandiser
Departmental Stores
Mono-brand Stores
Specialty Stores
Online Sales Channel
Global Human Milk Oligosaccharides (HMO) market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive human milk oligosaccharides hmo market market research and competitor analysis for your business to help you develop more profound insights into the human milk oligosaccharides hmo market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the human milk oligosaccharides hmo market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.